{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:08:22Z","timestamp":1789715302158,"version":"4.0.1"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To evaluate morbidity, mortality, maximum-tolerated dose (MTD), and outcome of intraoperative intracavitary hyperthermic cisplatin lavage in patients undergoing pleurectomy for malignant pleural mesothelioma (MPM). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Sixty-one patients were prospectively registered. Forty-four resectable patients with MPM underwent pleurectomy, followed by a 1-hour lavage of the resection cavity with dose-escalated cisplatin (50, 100, 150, 175, 200, 225, and 250 mg\/m<jats:sup>2<\/jats:sup>) at 42\u00b0C and then intravenous sodium thiosulfate (16 g\/m<jats:sup>2<\/jats:sup> over 6 hours). Survival estimates were compared using the log-rank test and proportional hazards regression. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Median age was 71 years (range, 50 to 82 years). Twenty-four patients had epithelial tumors, and 20 had sarcomatous or mixed histology. Postoperative mortality was 11% (five of 44 patients). Dose-limiting renal toxicity occurred at 250 mg\/m<jats:sup>2<\/jats:sup>, establishing the MTD at 225 mg\/m<jats:sup>2<\/jats:sup>. Other morbidity included atrial fibrillation (14 of 44 patients, 32%) and deep venous thrombosis (four of 44 patients, 9%). Median survival time of all registered patients was 9 months, and the median survival time of resected patients was 13 months. Survival estimates differed significantly for resectable patients exposed to low doses (50 to 150 mg\/m<jats:sup>2<\/jats:sup>; n = 9; median, 6 months) versus high doses (175 to 250 mg\/m<jats:sup>2<\/jats:sup>; n = 35; median, 18 months) of hyperthermic cisplatin (P = .0019); recurrence-free interval also differed significantly (4 v 9 months, respectively; P &lt; .0001). Low dose level (relative risk = 3.418) and nonepithelial histology (relative risk = 2.336) were independent risk factors for poor survival. Twenty patients with epithelial tumors who underwent high-dose cisplatin lavage had a 26-month median survival time. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Pleurectomy and high-dose intraoperative intracavitary hyperthermic cisplatin lavage is feasible in this patient population with restricted surgical options. An apparent dose-related survival benefit warrants further study. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.6813","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T00:02:51Z","timestamp":1143763371000},"page":"1561-1567","source":"Crossref","is-referenced-by-count":176,"title":["Phase I to II Study of Pleurectomy\/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma"],"prefix":"10.1200","volume":"24","author":[{"given":"William G.","family":"Richards","sequence":"first","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Zellos","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Jaklitsch","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R.","family":"Chirieac","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beow Y.","family":"Yeap","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene J.","family":"Dekkers","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Hartigan","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Capalbo","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Sugarbaker","sequence":"additional","affiliation":[{"name":"From the Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.1143"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(99)70469-1"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(96)01008-1"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(01)00995-2"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37377"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-3944(00)00253-4"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2000.0978"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891001)64:7<1422::AID-CNCR2820640710>3.0.CO;2-T"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1159\/000227208"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(94)00614-D"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(99)70297-7"},{"key":"R15","unstructured":"Howell SB, Taetle R: Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64:611,1980-616,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(85)90285-8"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1156"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1177\/030089169608200111"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(92)90654-M"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1007\/BF02306613"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930600410"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.802"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.695"},{"key":"R25","unstructured":"Take H, Kubota K, Tamura K, et al: Activation of circulating platelets by hyperthermal stress. Eur J Med Res 1:562,1996-564,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1080\/026567399285738"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.3109\/02656739609023687"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.6813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:16:08Z","timestamp":1653513368000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.6813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,4,1]]}},"alternative-id":["10.1200\/JCO.2005.04.6813"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.6813","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}